A report recently released by Transparency Market Research, a U.S.-based market intelligence firm, highlighted the remarkable growth potential of the global radiopharmaceutical market, driven primarily by a sharp increase in the cancer incidence rate. Unlike more commonplace imaging techniques such as MRI, CT or ultrasound, the use of radiopharmaceuticals as biological tracers in conjunction with PET or SPECT machines allows for the mapping of metabolic and physiological activities. This is particularly useful in the diagnosis of cancer, since cancer cells operate at a higher metabolic rate than normal cells. Despite the strongly optimistic forecast, the radiopharmaceutical market continues to struggle with logistic challenges caused by regulatory issues, supply disruptions and transportation delays, according to the report.
See the original article on WHATECH for more information about the report.